MRNA vaccine takes on Virus-Linked cancers in new early trial
NCT ID NCT07349836
First seen Jan 25, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus (EBV), such as nasopharyngeal cancer, gastric cancer, and certain lymphomas. The treatment aims to train the immune system to recognize and attack EBV-positive cancer cells. Up to 40 participants will receive the mRNA vaccine alone or combined with a checkpoint inhibitor to see if it is safe and helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.